接受表柔比星、顺铂和卡培他滨治疗的胆管癌患者的单核苷酸多态性与临床结局
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
作者信息
Pacetti Paola, Giovannetti Elisa, Mambrini Andrea, Nannizzi Sara, Orlandi Massimo, Tartarini Roberta, Del Freo Alfonso, Del Tacca Mario, Danesi Romano, Cantore Maurizio
机构信息
Department of Oncology, Carrara City Hospital, Piazza Sacco e Vanzetti, 54033 Carrara (MS), Italy.
出版信息
Anticancer Res. 2009 May;29(5):1835-40.
BACKGROUND
Biliary tract carcinoma (BTC) is a rare highly malignant neoplasia. Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing group-1 (ERCC1) and X-ray repair cross complementing group 1 (XRCC1) genes were evaluated and correlated with clinical outcome.
PATIENTS AND METHODS
Thirty-three patients with BTC were treated with intravenous or intra-arterial cisplatin and epirubicin and oral capecitabine. The ERCC1-C118T, XPD-Asp312Asn, XPD-Lys751Gln and XRCC1-Arg399Gln polymorphisms were studied.
RESULTS
A partial response (PR) occurred in 6 patients. The median progression-free (PFS) and overall survival (OS) were 4.8 and 18.9 months, respectively. No significant correlations were observed between response, PFS and OS in patients grouped according to all the studied polymorphisms. The analysis of survival starting from diagnosis resulted in a significant association of the XRCC1-Arg399Arg variant with a shorter survival.
CONCLUSION
A role of the XRCC1-Arg399Gln polymorphism as a possible prognostic factor in patients affected by BTC is suggested.
背景
胆管癌（BTC）是一种罕见的高恶性肿瘤。对着色性干皮病D组（XPD）、切除修复交叉互补组1（ERCC1）和X射线修复交叉互补组1（XRCC1）基因的多态性进行了评估，并与临床结果相关联。
患者与方法
33例BTC患者接受静脉或动脉顺铂和表柔比星治疗以及口服卡培他滨。研究了ERCC1-C118T、XPD-Asp312Asn、XPD-Lys751Gln和XRCC1-Arg399Gln多态性。
结果
6例患者出现部分缓解（PR）。无进展生存期（PFS）和总生存期（OS）的中位数分别为4.8个月和18.9个月。根据所有研究的多态性分组的患者中，在缓解、PFS和OS之间未观察到显著相关性。从诊断开始的生存分析结果显示，XRCC1-Arg399Arg变异与较短生存期存在显著关联。
结论
提示XRCC1-Arg399Gln多态性可能作为BTC患者的一个预后因素发挥作用。
Zotero 插件